Allscripts-Misys (MDRX) Resumes, Shares Higher in Late Trading
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St awaits Nvidia's AI verdict after hot inflation data
- Oil rises as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Allscripts (MDRX) Tops Q3 EPS by 5c; Withdrawing Guidance; to Evaluate Alternatives
November 8, 2012 4:06 PM ESTAllscripts (NASDAQ: MDRX) reported Q3 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $360.7 million versus the consensus estimate of $372.35 million.
The company is withdrawing guidance.
CEO Glen Tullman continued, "We are... More
Allscripts-Misys Healthcare Solution (MDRX) halted, news pending
November 8, 2012 4:02 PM ESTAllscripts-Misys Healthcare Solution (NASDAQ: MDRX) halted, news pending... More
